December 11, 2006 (Orlando) — Clinicians have a new biological prognostic indicator that is more specific than the classic risk factors of older age and risk of thrombosis. Researchers ...
A new report found only about 2.8% of people with myelodysplastic syndromes (MDS) have JAK2 mutations. A new report is shining a light on an uncommon—but potentially meaningful—characteristic of some ...
QIAGEN 's QGEN ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) received FDA approval for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs). In this cancer group, blood cells in ...
The FDA grants 510(k) clearance for Qiagen's (NYSE:QGEN) ipsogen JAK2 RGQ PCR Kit for additional use in the diagnosis of all myeloproliferative neoplasms, a group of cancers in the bone marrow that do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results